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Available oline 13 January 2011Current therapeutic regimes for metastatic melanoma have failed to provide robust clinical
responses. Dasatinib has shown anti-proliferative and anti-invasive effects in vitro;
however, not all melanoma cells tested were sensitive to dasatinib. We used 2D-DIGE
analysis of phospho-enriched fractions to identify phosphoproteins involved in regulating
response to dasatinib in an isogenic pair of melanoma cell lines, one sensitive to dasatinib
(WM-115) and the other resistant (WM-266-4). In WM-115 cells treated with dasatinib, 18
unique protein species with altered phosphorylation levels were detected. Dasatinib
treatment of WM-266-4 cells resulted in phosphoprotein alterations to four unique
protein species. Four phosphorylated forms of Annexin-A2 (ANXA2) were increased in
WM-115 cells treated with dasatinib, whilst dasatinib treatment did not alter ANXA2
phosphoprotein levels in WM-266-4 cells. Immunoblotting confirmed that phosphorylation
of ANXA2, on tyrosine residues, was increased in WM-115 cells treated with dasatinib.
Subsequent knockdown of ANXA2 by siRNA significantly inhibited proliferation of WM-115
cells but did not significantly reduce proliferation of WM-266-4 cells. Therefore, ANXA2
plays a role in regulating proliferation in dasatinib-sensitive WM-115 cells and could
potentially play a role in sensitivity to dasatinib in melanoma cells.
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ANXA21. Introduction
The prevalence of skin cancer is increasing and it is now the
most frequent form of cancer in young people. Whilst
melanoma skin cancer occurs worldwide at a rate of 132,000
cases each year [1], non-melanoma skin cancer makes up the
majority of recorded cases with between 2 to 3 million cases
diagnosed each year (www.who.int).
The increase in the number of diagnosed cases of
melanoma can be explained by work and social practices;ax: +353 17005484.
.J. Eustace), Paul.Dowling
ynes@dcu.ie (M. Clynes),
l Dowling.
ier B.V. All rights reservepeople are spending more time outside, in direct contact with
sunlight. The associated exposure to powerful sunshine has
been identified as a major cause of melanoma development
[2].
The incidence of melanoma has increased over the last
four decades, with current rates varying between 15 and 60
per 100,000 [3]. In 2006 there were 60,000 new cases of
cutaneous melanoma in the European Union, and in 13,000
deaths (www.europeancancerleagues.org). Metastatic mela-
noma in its disseminated form is largely untreatable by@dcu.ie (P. Dowling), Michael.Henry@dcu.ie (M. Henry),
John.Crown@icorg.ie (J. Crown), Norma.ODonovan@dcu.ie
d.
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new therapeutic strategies to improve prognosis and iden-
tification of novel targets is critical for providing alternative
treatment options.
Dasatinib is a potent inhibitor of BCR-Abl, SRCkinases, C-Kit,
PDGFR, and ephrin-A receptor kinases[6], with an IC50 of 0.5 nM
for SRC (IC50 of <30 nM for the other targets) [6]. It has shown
good pre-clinical activity in several cancer types including
melanoma, breast, and colon cancer [7–9]. Dasatinib inhibits
the growth of melanoma cell lines and reduces tumour cell
migration and invasion in vitro [9–11]. SRC kinase, a target of
dasatinib, is known to regulate both the growth and invasive
capability of cancer cells [12]. Although inhibition of SRC kinase
is implicated in response to dasatinib, specific mechanisms of
response and resistance to dasatinib in melanoma cells are not
yet known.
Proteomics-based screening of cell line models is an
extensively used and successful approach for identifying
proteins associated with drug resistance. Previously, Hong
et al. and Tang et al. have employed 2D-DIGE coupled with
phosphoprotein enrichment to study signal transduction path-
ways, in particular, identification of signal-induced changes in
protein modification [13,14]. As dasatinib inhibits kinase-based
signalling, we focussed on examining changes in phosphoryla-
tion levels in dasatinib-sensitive and resistant cells in response
to treatment, in order to identify novel proteins and/or
signalling pathways associated with response or resistance.
We analysed the effects of dasatinib treatment in an
isogenic melanoma model. WM-115 was derived from a
vertical phase primary melanoma tumour and is dasatinib-
sensitive, and WM-266-4 was derived from a lymph node
metastatic tumour from the same patient [15] and is
dasatinib-resistant. We combined phosphoprotein enrich-
ment with 2D-DIGE technology and mass spectrometry (MS)
to investigate phospho-proteome changes caused by dasatinib
treatment in the two isogenic melanoma cell lines.2. Materials and methods
2.1. Cells and reagents
WM-115 and WM-266-4 were obtained from the European
Collection of Cell Cultures (ECACC). Cell lines weremaintained
at 37 °C with 5% CO2 in MEM supplemented with 10% FCS,
2 mML-glutamine, 1 mM NEAA, and 1 mM sodium pyruvate.
Stock solutions of dasatinib (10 mM) (Sequoia Research
Products) were prepared in dimethyl sulfoxide (Sigma-
Aldrich).
2.2. Proliferation assay
Proliferation was measured using an acid phosphatase assay.
For WM-266-4 cells, 1×103 cells/well were seeded in 96-well
plates, whilst WM-115 were seeded at 2×103 cells/well. Plates
were incubated overnight at 37 °C followed by addition of drug
at the appropriate concentrations and incubated for a further
5 days until control wells were 80% to 90% confluent. Allmedia
was removed and the wells were washed once with PBS.
10 mM paranitrophenol phosphate substrate (Sigma Aldrich)in 0.1 M sodium acetate buffer with 0.1% Triton X (Sigma
Aldrich) was added to each well and incubated at 37 °C for
2 hours. 50 μl of 1 M NaOHwas added and the absorbance was
read at 405 nM (reference—620 nM), as previously described
[9].
2.3. Phospho-enrichment and preparation for 2D
electrophoresis
WM-115 and WM-266-4 cells were grown in vented 175 cm2
flasks until 90% confluent. Each cell line was then either
treated for 6 hours with dasatinib at a concentration of 100 nM
or with control growth media. Triplicate samples of each
treatment were prepared. Total protein was extracted and the
phosphoproteins were enriched using the PierceTM Phospho-
protein Enrichment Kit (Pierce Biotechnology). Briefly, cells
were washed twice with cold HEPES buffer (50 mM, pH 7) and
lysed using the Lysis/Binding/Wash buffer provided. The lysis
buffer was supplementedwith CHAPS (0.25%), sodiumdodecyl
sulphate, 0.1% SDS, 1X Halt Protease Inhibitor EDTA-free and
1X Halt Phosphatase Inhibitor Cocktail (Pierce Biotechnology).
After cell scraping, the lysates were placed on ice for
45 minutes, vortexing every 5 minutes and the resulting lysate
was passed through an 18-gauge needle. The lysate was
centrifuged at 10,000×g for 20 minutes at 4 °C and the
supernatant collected and stored at −80 °C. After protein
quantification by BCA assay, the concentration of each lysate
was adjusted to 0.5 mg/ml and the phosphoprotein fraction of
each was enriched using phosphoprotein enrichment col-
umns supplied with the kit, according to the protocol
provided. The eluted phosphoprotein fractions were concen-
trated using iCON concentrators (Thermo Scientific), yielding
100–150 μl of concentrated phosphoprotein for each sample.
Proteins in the phospho-enriched fraction were precipitated
prior to labeling using a 2D-Cleanup Kit (Biorad). The protein
pellets were resuspended in ice-cold DIGE lysis buffer [20 mM
Tris, 7 M Urea, 2 M Thiourea, 4% CHAPS pH 8.5]. Protein
quantification was performed using the Quick Start Bradford
Protein Assay (Biorad) and bovine serum albumin as a protein
standard.
Concentrated elution fractions were resolved on 10% SDS-
PAGE gels and were normalised by protein concentration (7 μg
of protein per lane). To determine enrichment of both the
untreated and dasatinib-treated WM-266-4 cell line, crude,
void and enriched lysates were loaded onto each gel. A
Phospho-specific antibody (Phospho-MAPK Tyr 204, (Cell
Signalling Technology)), recognising a key regulatory protein
involved in cell signalling through the ERK pathway was used
to monitor binding specificity and enrichment of the Pierce
Phosphoprotein Enrichment Kit. Total MAPK was also used as
a control.
2.4. Two-dimensional-differential in-gel electrophoresis
(2D-DIGE)
During this investigation, a traditional three-dye system was
employed to reduce variability associated with the multiple
samples being compared [16]. Phospho-enriched samples
were labeled with N-hydroxy succinimidyl ester derivatives
of the cyanine dyes Cy2, Cy3, and Cy5 following a standard
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strips, pH 3-11NL, were rehydrated in rehydration buffer (7 M
Urea, 2 M Thiourea, 4% CHAPS, 0.5% IPG Buffer, 50 mM DTT)
overnight, according to the standard guidelines. Iso-Electric-
Focusing (IEF) was performed using an IPGphor apparatus (GE
Healthcare) for a total of 40 kV/hour at 20 °C. Equilibrated IPG
strips were transferred onto 12.5% uniform polyacrylamide
gels poured between low fluorescence glass plates. Strips were
overlaid with 0.5% w/v low-melting-point agarose in running
buffer containing bromphenol blue. Gels were run using the
Ettan Dalt 12 apparatus (GE Healthcare) at 2.5 W/gel for
30 minutes then 100 W in total at 10 °C until the dye front
had run off the bottom of the gels.
2.5. Image acquisition and analysis
After second-dimension SDS-PAGE, gels were scanned using
the Typhoon 9400 variable mode imager (GE Healthcare). Cy2
protein maps were scanned using a 488-nm laser with a
530-nm emission filter; Cy3 was scanned using a 532-nm laser
with a 605-nm emission filter; Cy5 was scanned using a
635-nm laser with a 695-nmemission filter. Gels were scanned
at 100 μm resolution. Image analysis was performed using the
DeCyder™ Software version 6.5 (GE Healthcare). Gel-to-gel
matching of the standard protein maps from each gel,
followed by statistical analysis of differential protein abun-
dance between samples, was determined using the biological
variation analysis module (BVA) of DeCyder™. Analysis of
variance (ANOVA) was applied to matched spots and the data
were filtered to retain protein spots with p≤0.05 determined
by 1-way ANOVA and a fold-change of ≥1.2. Using the EDA
Version 1.0 (extended data analysis) module within the
DeCyder software (GE Healthcare), data analysis was
performed using principal components analysis (PCA) on
proteins of interest [18].
2.6. Mass spectrometry and database searching
Preparative gels containing 400 μg of protein were fixed and
thenpost-stainedwithColloidal Coomassie Blue (CCB). TheCCB
stained gels were scanned using the Typhoon 9400 Variable
Mode Imager using the red laser without an emission filter. The
subsequent gel imagewas cropped (ImageQuant), imported into
the BVA module of DeCyder software and was matched to
images generated from DIGE analysis. Spots of interest were
selected and a pick list was generated and imported into the
software of the Ettan Spot Picker robot (GE Healthcare).
Proteins of interest were excised from preparative gels and
subjected to digestion with trypsin (Promega). The peptides
resulting from tryptic digestion were subsequently desalted
using ZipTipsC18 (Millipore) and eluted with a saturated
solution of cyano-4-hydroxycinamic acid (CHCA; Sigma) dis-
solved in 50% acetonitrile and 0.1% TFA onto a 384-well MALDI
plate. Samples were analysed using a 4800 Proteomics Analyzer
(Applied Biosystems) and GPS Explorer software (Applied
Biosystems). For MALDI-TOF/TOF-MS analysis, MS spectra
were acquired in reflectron mode using 1000 shots per
spectrum. Instrument calibrations were performed externally
using the Pep4 calibrationmixture (Laser Biolabs) and internally
by the use of trypsin autolysis peaks (842m/z, 1045m/z, and2211m/z). Themass range usedwas 800–3000m/z. Data Explorer
4.4 (Applied Biosystems) was used for data acquisition and
extraction of the monoisotopic masses. MS/MS analysis was
performed by selecting 10 precursorswith aminimumS/N ratio
of 40. Fragmentation of selected precursorswas performedwith
the collision energy set at 2 kV and atmosphere as the collision
gas. A total of 1000 acquisitions were accumulated for eachMS/
MS spectrum. Combined MS and MS/MS spectra were used to
search for protein candidates using the UniProtKB/Swiss-Prot
(Release 57.5) and NCBI-nr (April 2009 version) human protein
databaseswith theMatrix Science offeredMascot search engine
(http://www.matrixscience.com). The Mascot search para-
meters were (a) species, Homo sapiens; (b) allowed number of
missed cleavages, 1; (c) fixed modification, carbamidomethyl
cystein; (d) variable modifications, methionine oxidation, and
serine/threonine/tyrosine (STY) phosphorylation; (e) peptide
tolerance, ± 50–100 ppm; (f) MS/MS tolerance, ± 0.3 Da; and (g)
peptide charge, +1.
Proteins not identified conclusively using MALDI-TOF/TOF
MS were subjected to analysis by LC-MS. The dried peptide
extracts were dissolved in 30 μl of 0.1% formic acid in 2%
acetonitrile and analysed by nanoLC-MS/MS using anUltimate
3000 system (Dionex) coupled to a nanospray LTQ Orbitrap
mass spectrometer (Thermo Fisher Scientific). 8 μl of each
sample was concentrated and desalted on RPC trap columns
(Zorbax 300SB C18, 0.3 mm×5 mm, Agilent Technologies, and
the peptides were separated on a nano-RPC column (Zorbax
300SB C18, 0.075 mm×100 mm, Agilent Technologies) using a
linear acetonitrile gradient from 0% to 65% ACN (Sigma) over
60 minutes. All buffers used for nano LC separation contained
0.1% formic acid (Fluka) as the ion pairing reagent. The flow
rate was set at 300 nl/minute. The LTQ Orbitrap was operated
in data-dependent acquisition mode with Xcalibur software.
Survey scanMS data were acquired in the Orbitrap on the 300–
2000m/zmass rangewith the resolution set to a value of 60,000
at m/z 400. The five most intense ions per survey scan were
selected forMS/MS fragmentation and the resulting fragments
were analysed in the linear trap. Collision energy was set to
35%. Dynamic exclusion was employed within 60 seconds to
prevent repetitive selection of the same peptide. Full scan
mass spectra were recorded in profile mode and tandemmass
spectra in centroid mode. The peptides were identified using
the information in the tandem mass spectra by searching
against the UniProtKB/Swiss-Prot (Release 57.5) and NCBI-nr
(April 2009 version) human protein databases using SEQUEST.
For protein identification, artificial modifications of peptides
(carbamidomethylation of cysteines, partial oxidation of
methionines, and serine/threonine/tyrosine (STY) phosphor-
ylation) were considered. Searches were also carried out
allowing for one missed cleavage and mass tolerances in MS
and MS/MS were set to 10 ppm and 0.5 Da, respectively.
Criteria for positive identification of proteins included at
least two identified peptides and a peptide XCorr of >2 for
doubly charged ions, >2.2 for triply charged ions, and >3 for
quadruply charged ions.
2.7. Protein extraction
500 μL RIPA buffer (Sigma-Aldrich) with 1× protease inhibitors,
2 mM phenylmethanesulphonylfluoride (PMSF), and 1 mM
493J O U R N A L O F P R O T E O M I C S 7 4 ( 2 0 1 1 ) 4 9 0 – 5 0 1sodium orthovanadate (all Sigma-Aldrich) was added to cells
and incubated on ice for 20 minutes. Following centrifugation
at 16,000×g for 5 minutes at 4 °C the resulting lysatewas stored
at −80 °C. Protein quantification was performed using the
Quick Start Bradford Protein Assay (Biorad) using bovine
serum albumin as a protein standard.
2.8. Coomassie staining
10 μg protein in sample buffer (3.12 m M Tris–HCl; 5% Sodium
dodecyl sulphate (SDS); 2.5 ml beta-mercaptoethanol; 29%
glycerol; 0.1% bromophenol blue made up to 20 ml with
dH2O) was heated to 95 °C for 5 minutes and loaded onto 12%
NuPAGE Bis–Tris gels (Invitrogen) and electrophoretically
separated using a MOS/SDS buffer. The samples were run
according to the manufacturer's instructions and were
stained using CCB (Sigma). The gel was scanned on
an Image Scanner (GE Healthcare) using LabScan v5.0 (GE
Healthcare).
2.9. Western blotting
40 μg of protein in sample buffer (3.12 mMTris–HCl; 5% sodium
dodecyl sulphate (SDS); 2.5 ml beta-mercaptoethanol; 29%
glycerol; 0.1% bromophenol blue made up to 20ml with dH2O)
was heated to 95 °C for 5 minutes and proteins were separated
on10%polyacrylamidegels (Lonza). Theproteinwas transferred
to Hybond-ECL nitrocellulose membrane (Amersham Bios-
ciences). The membrane was blocked with 5% milk powder
(Biorad) in 0.1% PBS-Tween at room temperature for 1 hour,
then incubated overnight at 4 °C in 1 μg/ml primary antibody
for ANXA2 (BD Biosciences); phosphotyrosine, phosphoser-
ine, SRC kinase, p-SRC (Y418) (Millipore), p-MAPK (Tyr 204),
MAPK (Cell signalling) and α-tubulin (Sigma Aldrich) with
0.1% PBS-Tween in 5% milk powder. The membrane was
washed three times with 0.5% PBS-Tween and then incubat-
ed at room temperature with 1 μg/ml anti-mouse secondary
antibody (Sigma Aldrich) for ANXA2, phosphotyrosine,
phosphoserine, SRC and α-tubulin and 0.3 μg/ml anti-rabbit
secondary antibody (Sigma Aldrich) for p-SRC (Y418), p-MAPK
(Tyr 204), and MAPK in 5%milk powder with 0.5% PBS-Tween
for 1 hour. The membrane was washed three times with 0.5%
PBS-Tween followed by one wash with PBS alone. Detection
was performed using Luminol (Santa Cruz Biotechnology) or
ECL Advance (GE Healthcare).
2.10. Immunoprecipitation
Immunoprecipitation was performed using the Catch and
Release® reversible immunoprecipitation system (Millipore).
Briefly, spin columns were washed 3 times with 400 μl of 1X
Catch and Release wash buffer. 500 μg of cell lysate was added
to the column together with 2–3 μg of antibody per sample,
10 μl of Catch and Release antibody ligand and the final
volume was made up to 500 μl with 1X wash buffer. Capped
sample columnswere then incubated overnight on a shaker at
4 °C. Columns were centrifuged at 2000×g for 30 seconds,
washed with 400 μl 1X wash buffer, centrifuged again at
2000×g for 30 seconds and the supernatant removed. This
process was repeated twice. 70 μl of denaturing elution bufferwith 5% beta-mercaptoethanol was added and incubated for
5 minutes. The column was centrifuged for 1 minute at
2000×g. This procedure was repeated three times and each
eluent collected into a separate tube. Samples were heated to
95 °C for 5 minutes and stored at − 20 °C.
2.11. Small interfering RNA (siRNA) transfection
A siRNAmolecule targeting kinesin and a scrambled sequence
siRNA molecule (Ambion) were used as positive and negative
transfection controls. Each siRNAmolecule was transfected at
a final concentration of 30 nM. 5×104 and 1.5×105 cells were
resuspended in MEM media for 24-well and 6-well plates
respectively and incubated overnight at 37 °C. Each siRNA
(ANXA2 siRNA-ON-TARGETplus SMART pool (Thermo); kine-
sin and scrambled (Applied Biosystems)) and Lipofectamine
2000 transfection agent (3 μl for 6-well plates; 0.75 μl for 24-
well plates) were diluted in GibcoTM Opti-MEM reduced serum
medium (Invitrogen), and incubated at room temperature (RT)
for 5 minutes. Diluted Lipofectamine 2000 was added to each
diluted siRNA and incubated for a further 20 minutes at RT
and the transfection mix was then added. After 24 hours, the
transfection media was replaced with MEM media supple-
mented with 10% FCS. Six-well plates were used to prepare
lysates after 72 hours. Cells in 24-well plates were harvested
after 72 hours and counted using Guava Viacount (Millipore)
on the Guava EasyCyte.3. Results
3.1. Sensitivity to dasatinib in WM-115 and WM-266-4
melanoma cell lines
In proliferation assays, the primary melanoma cell line WM-
115 displayed greater sensitivity to dasatinib than the meta-
static cell line WM-266-4, which is derived from the same
patient [15]. The concentration of dasatinib required to inhibit
50% of the proliferation (IC50) of WM-115 was of 79.3 nM
(±11.7 nM). In WM-266-4 cells, dasatinib did not achieve 50%
inhibition of growth. The maximum growth inhibition
achieved was 13% at 100 nM dasatinib (Fig. 1A). SRC is
expressed and phosphorylated on tyrosine 418 (Y418) in both
WM-115 and WM-266-4 cells (Fig. 1B). Treatment with 100 nM
dasatinib for 6 hours resulted in the inhibition of activation of
p-SRC Y418 levels in both cells lines. The reduction in p-SRC
activation occurred regardless of the effect that dasatinib had
on proliferation levels.
3.2. Phosphoproteomic profiling of dasatinib-treated cells
To demonstrate phosphoprotein enrichment using the PierceTM
Phosphoprotein Enrichment Kit, a 1D gel was run using crude,
void, and phosphoprotein-enriched samples. The void samples
were the flow-through from the phosphoprotein enrichment
column and therefore should contain little phosphorylated
protein. The Coomassie -stained gel demonstrated that all 3
proteome fractions are different indicating that fractionation of
the crude sample using the enrichment kit was successful
(Fig. 1C). Further Western blot analysis of the equally loaded
Fig. 1 –A.%Growth inhibition ofWM-115 andWM-266-4 cells
when treated with 100 nM dasatinib in a 5-day growth assay
as determined by acid phosphatase. B.Western blotting
analysis of SRC kinase and α-tubulin expression and levels
of p-SRC Y418 in WM-115 and WM-266-4 cells with and
without 100 nMdasatinib for 6 hours.C.ACoomassie stained
gel displaying the crude (C), void (V), and phospho-enriched
(E) fractions of WM-266-4 cells with and without dasatinib
treatment separated by 1D gel fractionation.Western blotting
analysis of p-MAPK (Y204) and MAPK in crude (C), void (V),
and phospho-enriched (E) fractions of WM-266-4 cells with
and without dasatinib treatment.
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266-4 cells, with andwithout dasatinib treatment, were analysed
usingaphospho-specific antibody recognisingmitogen-activated
protein kinase (p-MAPK). Western blotting demonstrated an
increased level of phosphorylated MAPK protein in samples of
both phospho-enriched WM-266-4 parental and drug-treated
cells, compared to the crude and void fractions (Fig. 1C). Incuba-
tionof theblotswithanantibody to totalMAPKdemonstrated the
presence of this protein in all samples.
UsingMASCOT and SEQUESTweb-based protein prediction
tools, we examined peptide modifications including phos-
phorylation. We detected potential phosphorylation sites in
16 of the 34 proteins analysed (47%) (Tables 1 and 2). This
suggests that the phosphoprotein enrichment procedureselectively increased phosphoproteins in the protein samples
analysed. Furthermore, the number of potential phosphory-
lation sites identified may have been limited by the sequence
coverage obtained for some of the proteins. For the 34 proteins
identified, the sequence coverage ranged from 7% to 69% with
an average coverage of 38%. Phosphorylation sites were only
identified on proteins which attained greater than 33%
sequence coverage (n=25). Of proteins with greater than 33%
sequence coverage, potential phosphorylation events were
detected in 64% (16/25) of cases.
Following 2D-DIGE analysis of phosphoprotein-enriched
lysates from WM-115, dasatinib-treated WM-115, WM-266-4
and dasatinib-treated WM-266-4 cells, approximately 1200
protein spots were detected on each gel (Fig. 2). Twenty-one
proteins, which were altered in WM-115 compared to dasati-
nib-treated WM-115 cells and WM-266-4 compared to dasati-
nib-treated WM-266-4 cells (≥1.2-fold, p≤0.05 determined by
1-way ANOVA), were excised from 2D gels, subjected to tryptic
digestion, and the resulting peptides were analysed by mass
spectrometry (MALDI-TOF/TOF or LC-MS). Of these 21 unique
protein species identified, 18 were found to be uniquely
associated with dasatinib treatment in the WM-115 cells and
demonstrated fold changes ranging from −2.98 to +7.03
(p≤0.05 determined by 1-way ANOVA) (Table 1). Four unique
phosphoproteins were found to be uniquely associated with
dasatinib treatment in the WM-266-4 cells, with fold changes
ranging from −1.64 to −1.22 (p≤0.05) (Table 2). Three phos-
phoproteins were altered in both cell lines in response to
dasatinib treatment, namely PRDX2, RDX, and GRP78.
The proteins that showed the greatest fold change in
response to dasatinib treatment in WM-115 cells included 2
spots identified as protein disulfide isomerase-related protein
5 (PDIA5), two moesin (MSN) and two radixin (RDX) isoforms,
which were all reduced in dasatinib-treated WM-115 cells
(Table 1). Dasatinib treatment of WM-115 cells also resulted in
increased abundance of 14 phosphoproteins, which were not
altered in dasatinib-treated WM-266-4 cells.
In WM-115 cells, treatment with dasatinib resulted in
increased abundance of 4 phospho-enriched isoforms of
Annexin-A2 (ANXA2) (3.06-fold, 3.02-fold, 2.17-fold, and 1.97-
fold) (Fig. 3A–D, spot numbers 26–29 from Table 1). None of
these ANXA2 isoforms were significantly altered in dasatinib-
treated WM-266-4 cells. Another isoform of ANXA2 was also
identified in our analysis (Fig. 3e). Dasatinib treatment of WM-
115 cells did not alter levels of this isoform (fold change, 1.10),
whilst dasatinib treatment of WM-266-4 cells resulted in a
slight decrease (fold change, −1.24) but this did not achieve
statistical significance.
The four phosphoprotein species uniquely altered in WM-
266-4 cells were decreased in response to dasatinib treatment.
The two proteins that showed the greatest fold changes were
annexin-A3 (ANXA3), which was decreased by 1.64-fold, and
highmobility group protein B1 (HMGB1), which was decreased
by 1.57-fold (Table 2).
3.3. Multivariate analysis
Multivariate analysis was performed, using the DeCyder-EDA
module. The analysis was performed on differentially regu-
lated proteins in untreated versus dasatinib-treated WM-115
Table 1 – Identified phosphoproteins uniquely altered in dasatinib-treated WM-115 cells. Phosphoproteins, which demonstrated a fold-change of≥1.2 and a significant
p value (≤0.05), were included for analysis.
Master no. Protein ID Gene Symbol Accession
number
Fold
change
p value XC-scorea Mascot
score b
%Sequence
coverage
Peptides
matched
LC/MS or
MALDI
TOF/TOF
STY
residue
modified
1 Moesin MSN 127234 −2.98 1.00e−30 90 – 33 9 LC/MS N
2 Peroxiredoxin 2 isoform b PRDX2 2507169 −2.69 2.07e−12 50 – 37 5 LC/MS Y
3 Radixin RDX 464541 −2.46 7.03e−12 120 – 33 12 LC/MS Y
4 Transketolase TKT 1729976 −2.38 1.00e−30 120 – 36 12 LC/MS Y
5 Moesin MSN 127234 −2.3 7e−005 – 93 33 9 MALDI Y
6 Radixin RDX 464541 −1.91 9.85e−10 100 – 26 10 LC/MS N
7 Serum Albumin ALB 113576 −1.9 6.7e−005 – 47 7 5 MALDI N
8 Protein disulfide isomerise-related protein 3 PDIA3 2507461 −1.9 2.6e−055 – 597 49 36 MALDI Y
9 Radixin RDX 464541 −1.84 2.82e−09 50 – 22 5 LC/MS N
10 Protein disulfide isomerise-related protein 5 PDIA5 1710248 −1.73 1.3e−006 – 110 31 15 MALDI N
11 Protein disulfide isomerise-related protein 5 PDIA5 1710248 −1.66 3.3e−006 – 106 31 14 MALDI N
12 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 120649 −1.44 1.82e−10 40 – 18 4 LC/MS N
13 Moesin MSN 127234 −1.41 1e−008 – 131 39 13 MALDI Y
14 Annexin A1 ANXA1 113944 −1.37 3.44e−14 140 – 55 14 LC/MS N
15 Pyruvate kinase M2 PKM2 5702302 −1.34 2.6e−012 – 167 69 4 MALDI Y
16 Glucose-6-phosphate 1-dehydrogenase G6PD 116242483 −1.34 2.03e−12 180 – 62 18 LC/MS N
17 Alpha-enolase ENO1 119339 −1.31 1.59e−08 40 – 29 4 LC/MS N
18 Protein disulfide isomerise-related protein 5 PDIA5 1710248 1.34 0.036 – 66 30 13 MALDI N
19 Peroxiredoxin-4 PRDX4 3024727 1.36 2.22e−14 80 – 38 8 LC/MS Y
20 Alpha-actinin-4 ACTN4 13123943 1.38 2.57e−07 40 – 7 4 LC/MS N
21 Annexin-A1 ANXA1 113944 1.4 2.6e−011 – 157 39 17 MALDI N
22 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 120649 1.43 3.33e−09 40 – 25 4 LC/MS N
23 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 120649 1.43 1.1e−15 232 – 68 16 LC/MS N
24 Actin B ACTB 15277503 1.51 1.3e−007 – 120 27 15 MALDI N
25 Stress-70 protein GRP75 21264428 1.79 5.55e−14 240 – 48 24 LC/MS Y
26 Annexin A2 ANXA2 113950 1.97 2.6e−013 – 177 35 18 MALDI N
27 Annexin-A2 ANXA2 113950 2.17 3.33e−16 – 251 50 23 MALDI Y
28 Annexin-A2 ANXA2 113950 3.02 8.2e−023 – 272 46 24 MALDI Y
29 Annexin-A2 ANXA2 113950 3.06 6.5e−038 – 613 63 32 MALDI Y
30 S100A10 S100A10 4388970 7.03 4.1e−009 – 135 41 8 MALDI Y
a Sequest XC-score for proteins identified by LC-MS.
b Mascot score for proteins identified by MALDI TOF/TOF.
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Table 2 – Identified phosphoproteins uniquely altered in dasatinib-treated WM-266-4 cells. Phosphoproteins, which
demonstrated a fold-change of ≥1.2 and a significant p value (≤0.05), were included for analysis.
Master
no.
Protein ID Fold
change
Gene
Symbol
XC-
scorea
Mascot
scoreb
%Sequence
coverage
p value Accession
number
Peptides
matched
LC/MS or
MALDI
TOF/TOF
STY
residue
modified
31 Annexin-A3 −1.64 ANXA3 110 – 38 2.03e−11 113954 11 LC/MS Y
32 High mobility group
protein B1
−1.57 HMGB1 40 – 54 1.84e−07 123369 4 LC/MS N
33 Heat shock cognate
71 kDa protein
−1.33 HSC71 140 – 34 1.67e−14 123648 14 LC/MS Y
34 Glucose-6-phosphate
1-dehydrogenase
−1.22 G6PD 116 – 55 2.86e−12 116242483 16 LC/MS Y
a Sequest XC-score for proteins identified by LC-MS.
b Mascot score for proteins identified by MALDI TOF/TOF.
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cells. Principal component analysis presents the greatest
variance of the data set on the abscissa (principal component
1, PC1, 69.9% of the variance) and the second greatest variance
of the data on the ordinate (principal component 2, PC2, 23.4%
of the variance). Together, both PC1 and PC2 accounted for
93.3% of the variance. Samples from each cell line clustered
together indicating limited variance within each group and
distinct differences between cell lines. The spot maps (scoreFig. 2 – Differentially regulated phosphoproteins associated with
the exact locations for the 34 differentially expressed phosphopr
with the WM-115/WM-115 dasatinib comparison and 4 uniquely
comparison) were subsequently identified by MALDI-TOF/TOF M
range 3–11 NL (left to right) and molecular weight range of appro
visual clarity and are outlined in Table 1 and Table 2.plot) from untreated WM-266-4 cells and dasatinib-treated
WM-266-4 cells clustered together, indicating limited variance
between these two phenotypes. However, untreated WM-115
and dasatinib-treated WM-115 cells cluster at different loca-
tions from each other and from both untreated and treated
WM-266-4 cells. This indicates that both untreated and treated
WM-115 cells are distinct from WM-266-4 and dasatinib-
treated WM-266-4 cells as well as from each other in terms of
consistent differences in phosphoprotein levels (Fig. 4).sensitivity or resistance to dasatinib. Preparative gel showing
oteins. These 34 phosphoproteins (30 uniquely associated
associated with the WM-266-4/WM-266-4 dasatinib
S or LC-MS (p<0.05 determined by 1-way ANOVA) in the pH
ximately 10–120 kDa. Proteins were labelled numerically for
Fig. 3 – Phospho-enriched Annexin-A2 isoforms inWM-115,WM-115 dasatinib-treated (WM-115 D),WM-266-4, andWM-266-4
dasatinib-treated (WM-266-4 D) cells. The y-axis represents the standardised log abundance of protein abundance.
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As several isoforms of ANXA2 were altered in response to
dasatinib treatment, ANXA2 was selected for further analysis
in the melanoma cell lines. ANXA2 protein was detected in
both WM-115 and WM-266-4 cell lines by Western blotting,
with slightly higher levels in WM-115 cells compared to WM-
266-4 cells (Fig. 5A). Based on previously published phospho-
proteomic analyses, ANXA2 has 5 potential serine phosphor-
ylation sites and 14 potential tyrosine phosphorylation sites
(www.phosphosite.org) [19]. Our 2D-DIGE phospho-proteomic
analysis indicated that the levels of ANXA2 phosphoproteins
are higher in WM-115 cells compared to WM-266-4 cells.
Furthermore, four of the identified phospho-ANXA2 spots
were significantly increased in WM-115 cells in response to
dasatinib treatment.
For identification of peptidemodifications of the 4 isoforms
of ANXA2, the search included phosphorylation (STY) modi-
fication analysis. We detected a number of potential phos-
phorylation sites in the 4 ANXA2 isoforms (Table 3). Two
potential phosphorylation sites, within residues 28–38, weredetected on spot 27, whilst one potential phosphorylation site
was detected on spot 29 in the same peptide (KAYTNFDAERD).
Three potential phosphorylation sites were detected on spot
28; one on peptide 232-245 (R.YKSYSPYDMLESIR.K) and two on
peptide 274–281 (R.LYDSMKGK.G). No potential phosphoryla-
tion sites were detected on spot 26.
Tyrosine phosphorylation of ANXA2 was assessed by
ANXA2 immunoprecipitation followed by immunoblotting
with an anti-phosphotyrosine antibody. Dasatinib treatment
resulted in a slight increase in ANXA2 phosphotyrosine levels
inWM-115 (Fig. 5B), whereas a slight decrease was observed in
dasatinib-treated WM-266-4 cells. Very low levels of serine
phosphorylation were detected on ANXA2 in both WM-115
and WM-266-4 cells.
Wealsoassessed theeffectsofANXA2siRNAonproliferation
in WM-115 and WM-266-4 cells. ANXA2 siRNA significantly
reducedANXA2expression (p=0.04) inWM-115 cells and caused
significant inhibition of proliferation in WM-115 cells (42.3±
12.3%, p=0.04) compared to the scrambled siRNA (Fig. 6).
ANXA2 siRNA also significantly reduced ANXA2 expression
compared to scrambled siRNA (p=0.01) in WM-266-4 cells
Fig. 4 – Principal component analysis (PCA) showing the
position of the four cell line samples, WM-115,
WM-115 D, WM-266-4, and WM-266-4 D based on the first
two ordination axes, PC1 (abscissa) and PC2 (ordinate). PC1
accounted for 69.9% of the variance and PC2 accounted for
23.4% of the variance. Together, both PC1 and PC2 accounted
for 93.3% of the variance.
Table 3 –Matched peptide information for identified
isoforms of ANXA2 proteins, showing fold change in
ANXA2 abundance between untreated and dasatinib-
treated WM-115 cells, MASCOT scores and %coverage
obtained for the matched peptides. Peptide sequences
with potential phosphorylation sites and the number of
potential phosphorylation sites detected are listed.
Residues marked as bold and underlined indicate
potential serine (S), threonine (T), or tyrosine (Y)
phosphorylation sites.
Protein I.D. 26 27 28 29
Fold change 3.02 1.97 3.06 2.17
MASCOT score 266 188 605 160
%Coverage 48% 51% 59% 45%
Total no. of potential phosphate
groups
0 2 3 1
Peptide sequences and no. of phosphate groups identified
11–28 K.LSLEGDHSTPPSAYGS
VK.A
0 0 0 0
28-38 KAYTNFDAERD 0 2 0 1
50–63 K.GVDEVTIVNILTNR.S 0 0 0 0
69–77 R.QDIAFAYQR.R 0 0 0
89–104 K.SALSGHLETVILGLLK.T 0
105–115 K.TPAQYDASELK.A 0 0 0 0
120–135 K.GLGTDEDSLIEIICSR.T 0 0 0 0
136–145 R.TNQELQEINR.V 0 0 0 0
153–168 K.TDLEKDIISDTSGDFR.K 0 0 0 0
179-196 R.RAEDGSVIDYELIDQD
AR.D
0 0 0 0
197–204 R.DLYDAGVK.R 0 0
213–220 K.WISIMTER.S 0
221–227 R.SVPHLQK.V 0
232–245 R.YKSYSPYDMLESIR.K 0 0 1
274–281 R.LYDSMKGK.G 2
296–302 R.SEVDMLK.I 0 0
314-324 K.SLYYYIQQDTK.G 0 0 0 0
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(13.8±8.5%, p=0.36) in WM-266-4 cells, compared to the
scrambled siRNA.Fig. 5 – Western blot analysis of (A) ANXA2 and α-tubulin in
WM-115 and WM-266-4 melanoma cell lines. (B) ANXA2
immunoprecipitation (IP) and detection of the ANXA2
tyrosine and serine residues by immunoblotting using
phosphotyrosine or phosphoserine antibodies in WM-115
and WM-266-4 cells with and without 100 nM dasatinib for
6 hours.4. Discussion
Proteomic approaches, based on comparative proteome profil-
ing of cell lines, demonstrate an effectivemethod of identifying
candidate proteins implicated in the sensitivity/resistance to
therapeutic drugs. 2D-DIGE is now recognized as an extremely
robustmethod in comparative proteomics to analyse anddetect
changes related to a variety of effects on the cellular proteome.
Dasatinib, a multi-target tyrosine kinase inhibitor, has
activity against several kinases including BCR-Abl, SRC kinases,
C-Kit, PDGFR, and ephrin-A receptor kinases [6]. In preclinical
studies, dasatinib has shown good anti-proliferative and anti-
invasive effects inmelanoma cell lines [9–11]. However, the pre-
clinical studies in melanoma cell lines have failed to identify
alterations in signalling pathways which determine sensi-
tivity or resistance to dasatinib therapy. Because dasatinib
inhibits phosphorylation of specific tyrosine kinases, we
performed 2D-DIGE proteomic analysis of phospho-enriched
samples to provide a global screen of the effects of dasatinib
on signalling pathways in a sensitive and resistant model of
melanoma.
In this study, phosphoprotein enrichment, 2D-DIGE sepa-
ration, and mass spectrometry identification were performed
to compare and analyse the alterations in abundance of
phospho-enriched proteins from an isogenic melanoma
Fig. 6 – (A) Western blot analysis of ANXA2 levels in siRNA
treated WM-115 cells. (B) Densitometry analysis of ANXA2
bands (normalized to α-tubulin). Error bars represent the
standard deviation of triplicate siRNA transfection
experiments. *Indicates that p≤0.05 for ANXA2 siRNA
compared to scrambled siRNA. (C) Effect of ANXA2 siRNA on
growth in WM-115 melanoma cell line. Error bars represent
the standard deviation of triplicate experiments. *Indicates
that p≤0.05 for ANXA2 siRNA compared to scrambled siRNA.
Fig. 7 – (A) Western blot analysis of ANXA2 in siRNA treated
WM-266-4 cells. (B) Densitometry analysis of ANXA2 bands
(normalized to α-tubulin). Error bars represent the standard
deviation of triplicate siRNA transfection experiments.
*Indicates that p≤0.05 for ANXA2 siRNA compared to
scrambled siRNA. (C) Effect of ANXA2 siRNA on growth in
WM-266-4 cells. Error bars represent the standard deviation
of triplicate experiments. *Indicates that p≤0.05 for ANXA2
siRNA compared to scrambled siRNA.
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laboratory dasatinib has been shown to reduce SRC kinase
phosphorylation after 6-hour treatment in several melanoma
cell lines [9]. SRC kinase has been previously shown to regulate
several key signalling pathways including the PI3/AKT signal-
ling pathway, which has been shown to have control over
proliferation and invasion [12]. Therefore, we examined the
effects of dasatinib on phosphorylation levels of proteins after
6 hours of treatment with dasatinib as alterations observed
may relate to changes associated with SRC kinase inhibition.
Differentially regulated phosphoproteins, which could poten-
tially be associated with modulating response to dasatinib,
were also identified.
In WM-115 cells, dasatinib treatment reduced the levels of
moesin (MSN) and radixin (RDX) phosphoproteins. Moesin and
radixin aremembers of the ezrin,moesin, radixin (ERM) family
of molecules involved in the association of actin filaments
with the plasmamembrane. Moesin is constitutively activated
by phosphorylation of threonine 555 [20] and the activation ofERM family members links actin filaments to CD43, CD44, and
ICAM-1 which are involved in adhesion [21]. Moesin is critical
for invasion in 3D matrices [22], and phosphorylation of
moesin has also been linked with invasion in endometrial
cells [23]. The alterations in MSN and RDX, observed in the
dasatinib-treated WM-115 cells, may play a role in the effects
of dasatinib on migration and invasion.
In the dasatinib-sensitive WM-115 cells, phosphoproteomic
analysis suggested that dasatinib treatment increases the level
of ANXA2 phosphoproteins, which is not observed in dasatinib-
resistant WM-266-4 cells. Treatment with dasatinib increased
phosphorylation levels of ANXA2 in WM-115 cells but not in
WM-266-4 cells, which suggests that phosphorylated ANXA2
may play a role in dasatinib sensitivity. ANXA2 can be
phosphorylated on both serine and tyrosine residues. Immuno-
blottinganalysis of phosphotyrosineandphosphoserinesuggest
that dasatinib increased phosphorylation of tyrosine residues in
WM-115 but not in WM-266-4 cells, whilst phosphorylation of
serine residues appeared tobe reducedbydasatinib treatment in
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phosphorylation detected were very low.
Analysis of the 4 identified ANXA2 isoforms suggested
that ANXA2 spot 27 and 29 may differ in the phosphorylation
status of the tyrosine (Y) 30 and/or threonine (T) 31 residues.
These phosphorylation events were not identified in either
ANXA2 spot 26 or 30. ANXA2 Y30 has been previously
identified by mass spectrometry but no functional role has
been identified for this residue (www.phosphosite.org). Phos-
phorylation of threonine 31 has not been previously reported
(www.phosphosite.org).
ANXA2 spot 28 may be phosphorylated at Y232, Y235, or
Y238 or at serine (S) residues 234, S236, or S243. No phosphor-
ylation eventswere identified in this regionof the protein (232–
245) in either spot 26 or 27; however, this peptide sequence
was not detected in the analysis of spot 29. Phosphory- lation
of Y236 has been previously associated with migration
[24]. The exact site of the phosphorylation was not
established during our analysis. Two potential phosphoryla-
tion events were also detected on ANXA2 spot 28, on
residues Y275 and S277. Phosphorylation of Y275 has previ-
ously been found to be altered in SRC transformed mice
[25]. However, this peptide sequence (274–281) was not
detected in the other three ANXA2 isoforms so it is unclear
whether these phosphorylation events are specific to this
isoform.
Spot 26 may be unphosphorylated or may have other
potential phosphorylation sites that were not detected in the
mass spectrometry analysis due to limited peptide coverage.
Phosphorylation ofANXA2atY23 is implicated in the control
of cancer cell motility. SRC kinase can directly phosphorylate
ANXA2 on Y23 [26,27], which may negatively modulate ANXA2
function and inhibit the ability of ANXA2 to bind F-actin [27].
However, another study showed that phosphorylation of
ANXA2 Y23 is essential for ANXA2 function and its association
with the endosome [19]. In our analysis of phosphorylation
events in the four ANXA2 isoforms detected, no phosphoryla-
tion events were detected at Y23.
Dasatinib, anSRCkinase inhibitor, has been shown to inhibit
the phosphorylation of SRC kinase at its active site Y418 and
should thus decrease phosphorylation of ANXA2 at Y23.
However, we did not detect phosphorylation of Y23 on the
four ANXA2 isoforms identified.
Contrary to the anticipated decrease in phosphorylation,
we observed increases in the abundance of three ANXA2
isoforms which are phosphorylated at alternative sites. The
alterations in signalling pathways resulting from dasatinib
inhibition of its targets have yet to be elucidated. However,
these changes may result in increases in ANXA2 phosphory-
lation at several uncharacterised sites.
Annexin-2 (ANXA2) is a substrate for PKC, PDGFR, and SRC
kinase and acts in a calcium-dependent manner to interact
with the cell surface and affect the movement of phospholi-
pids [28]. It is linked with invasion, metastasis, and angiogen-
esis in cancer [28]. ANXA2 is usually found in a tetrameric
construct consisting of two ANXA2 chains and two S100A10
chains. The ANXA2-S100A10 complex has a channel modu-
lating effect on the cell surface which can affect the
membrane interactions of lipids [29]. SRC kinase has been
shown to phosphorlyate both ANXA2 [26,27] and S100A10 [30].Expression of ANXA2 is increased in glioma, pancreatic, and
colorectal cancer, whilst its expression was reduced in prostate
cancer [28]. Lower levels of ANXA2 were detected in metastatic
lung tumours compared to primary lung tumours [28]. In our
study, lower levels of phosphorylated ANXA2 were detected in
themetastatic cell line,WM-266-4, compared to theprimary cell
line, WM-115. Further analysis of ANXA2 phosphorylation in
primary and metastatic melanoma tumour samples would be
required to determine if loss of ANXA2 phosphorylation is
associated with melanoma progression.
ANXA2 siRNA treatment has previously been shown to
reduce proliferation andmigration and to increase apoptosis in
a range of cancer cell types [31–35].We found that ANXA2 siRNA
caused significant inhibition of growth in the dasatinib-
sensitive WM-115 cells. In the dasatinib-resistant WM-266-4
cells a slight decrease in growth was observed with the ANXA2
siRNA treatment but the effect was not significant when
compared to treatment with a scrambled siRNA. These results
suggest thatANXA2mayplaya role in regulatingproliferation in
WM-115 cells but this regulation is lost or reduced inWM-266-4
cells. Further investigation will be required to elucidate the role
ofANXA2 in response todasatinib treatmentand todetermine if
ANXA2 could be used as a predictive or pharmacodynamic
biomarker for dasatinib treatment in melanoma patients.
Our study found that 2D-DIGE analysis was an effective
method to identify proteins with altered phosphorylation that
may play a role in sensitivity and resistance to dasatinib in an
isogenicmodel of sensitivity inmelanoma. Several isoforms of
ANXA2 were altered by dasatinib treatment and siRNA
knockdown of ANXA2 resulted in significant proliferation
inhibition in the dasatinib-sensitive cell line WM-115 whilst
there was only a slight decrease in proliferation in dasatinib-
resistant WM-266-4 cells. Therefore, ANXA2may play a role in
modulating response to dasatinib in melanoma.Acknowledgments
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